Skip to main content

Unable to load price data. Sorry.



CAPS Rating: No stars

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:TRMS.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

sleepyseth (99.12)
Submitted November 07, 2006

Buy this company before the earnings announcement. This will be their first quarter of steady positive earnings (actually their second positive quarter ever). The stock is down a lot over the past couple of years, but now the company is actually… More

zzlangerhans (98.68)
Submitted September 23, 2011

Trimeris has been surprisingly volatile for a company that supposedly got acquired in an all stock deal by a privately held company three months ago. The share price has been as high as 2.8 and as low as 1.8 since the deal was announced. I'd have… More



  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about TRMS.DL.

No one has written a Pitch for TRMS.DL stock yet. Tell us why you think TRMS.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in TRMS.DL.

No players have picked TRMS.DL yet. Tell us why you think TRMS.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for TRMS.DL.